The biguanide metformin has been used as first-line therapy in type 2 diabetes mellitus
(T2DM) treatment for several decades. In addition to its glucose-lowering properties and its …

Simple Summary This literature analysis is focused on the pleiotropic action associated with
metformin treatment. Precisely, metformin treatment exerts many health effects, mainly by …

Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia due to persistent insulin
resistance, resulting in elevated blood glucose levels. Metformin is the most prescribed oral …

Objectives Efficacy and compliance of type II diabetes treatment would greatly benefit from
dosage forms providing controlled release of metformin in the upper gastrointestinal tract. In …

Minimal physiologically based pharmacokinetic (mPBPK) models, consisting of system-
specific (eg, tissue volume and blood flow) and drug-related (eg, tissue-to-plasma partition …

Background A single dose of metformin administered 1 h prior to oral glucose challenge was
previously shown to reduce insulinaemic responses in horses with experimentally‐induced …

In pharmacokinetic (PK) analyses, the biological half-life T1/2 is usually determined in the
terminal phase after drug administration, which is readily calculated from the relationship …

Arginine: glycine amidinotransferase (AGAT) catalyzes mainly two reactions that generate 1)
L-homoarginine (hArg) from L-arginine and L-lysine (K harg) and 2) guanidinoacetate (GAA) …

Metformin, the only biguanide oral antidiabetic agent available, was first used clinically in
the late 1950s. Metformin remains the first-line pharmacologic treatment for type 2 diabetes …

The incidence of paediatric obesity continues to rise worldwide and contributes to a range of
diseases including cardiovascular disease. Obesity in children has been shown to impact …